Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile

Back

ESC Professional Premium Access

Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile

Session: Improving outcomes in heart failure: bench to bedside

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor H. Kondo (Yufu City, JP)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Hidekazu Kondo

Hasama Campus - Faculty of Medicine, Oita University, Yufu City (Japan)

0 follower

8 more presentations in this session

Are heart failure patients with mildly reduced ejection fraction treated according to current international guidelines?

Speaker: Doctor T. Schupp (Mannheim, DE)

The power of optimal medical therapy in heart failure with secondary mitral regurgitation

Speaker: Unknown A. Borrellas Martin (Barcelona, ES)

Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction

Speaker: Doctor F. Hofer (Vienna, AT)

Successful treatment of pulmonary hypertension and right heart failure by antibody-based functional blocking of the extra-domain A of fibronectin in a preclinical animal model

Speaker: Professor M. Franz (Rotenburg an der Fulda, DE)

Effects of colchicine treatment after myocardial infarction on top of standard therapy: evidence from a preclinical study

Speaker: Doctor A. Aimo (Pisa, IT)

Access the full session

Improving outcomes in heart failure: bench to bedside

Speakers: Doctor H. Kondo, Doctor T. Schupp, Unknown A. Borrellas Martin, Doctor F. Hofer, Professor M. Franz...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources